Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored vonoprazan-based Helicobacter pylori eradication therapy in adults with penicillin allergy
jRCTs031260485Recruiting
- Sponsor
- Yokohama City University
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of vonoprazan, clarithromycin, metronidazole and sitafloxacin in Helicobacter pylori infection (2 arms), sponsored by Yokohama City University. Primary endpoint: Eradication rate. Started Sep 2026; status: recruiting.
02
Drugs
vonoprazanclarithromycinmetronidazolesitafloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCTs031260485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260485.